Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SEC Will Not Pursue Shire In Replagal Securities Fraud Case

This article was originally published in The Pink Sheet Daily

Executive Summary

SEC files civil action against former Transkaryotic Therapies CEO Richard Selden, but will not take action against TKT’s new parent company.

You may also be interested in...



SEC’s TKT Investigation

Securities & Exchange Commission staff has preliminarily decided to recommend taking action against Transkaryotic Therapies for securities law violations, the company said

Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly

Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.

AstraZeneca Continues Pipeline Expansion Via Two Licensing Deals Totaling $800 Million

Agreements expand the firm’s position in the COPD space, while also entering obesity, diabetes and metabolic syndrome space.

Topics

UsernamePublicRestriction

Register

PS062906

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel